OTCMKTS:BVNRY Bavarian Nordic A/S (BVNRY) Stock Price, News & Analysis → Gold Set to EXPLODE! (From Gold Safe Exchange) (Ad) Free BVNRY Stock Alerts $8.44 -0.09 (-1.06%) (As of 05/29/2024 ET) Add Compare Share Share Today's Range$8.44▼$8.5450-Day Range$6.92▼$8.6652-Week Range$5.95▼$10.65Volume3,399 shsAverage Volume2,629 shsMarket Capitalization$1.98 billionP/E Ratio13.39Dividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsHeadlinesShort InterestStock AnalysisChartEarningsHeadlinesShort Interest Get Bavarian Nordic A/S alerts: Email Address Ad Crypto 101 Media[Urgent!] Generational Wealth GameplanA brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.Click here to get instant access to the guide About Bavarian Nordic A/S Stock (OTCMKTS:BVNRY)Bavarian Nordic A/S is a fully-integrated biotechnology company focused on vaccination technology. The company’s work is built around two primary platforms that provide numerous benefits to the health industry and individuals. The company’s primary technology is MVA-BN which stands for Modified Vaccine Ankara-Bavarian Nordic. This vaccination platform is a non-replicating platform, meaning that live-virus vaccines cannot reproduce and spread within the host. This is central to the platform's high tolerance rate. MVA-BN is approved as a smallpox and monkeypox vaccine in the US, Canada, and the EU. It is also included in the US Strategic National Stockpile and is being used worldwide to control the 2022 Monkeypox outbreak.Bavarian Nordic is headquartered in Hellerup, Denmark with manufacturing sites in Denmark and Germany. The company maintains offices in Switzerland, the UK, Japan, and North Carolina in the United States. The company was incorporated in 1992 and had 4 approved products under 7 brand names available for use. Its MVA-BN non-replicating smallpox and monkeypox vaccines are available under the IMVAMUNE, IMVANEX and JYNNEOS names.The company’s second platform is the Vaccinia-Fowlpox-TRICOM platform for treating cancers. The platform can be targeted to attack specific markers found in numerous cancers. The company’s other marketable vaccines are Rabipur for rabies, MVABEA for Ebola and Marburg Hemorrhagic fever, and Encepur for tick-borne encephalitis.The company’s pipeline has 4 potential candidates for the market. These include a freeze-dried version of MVA-BN for smallpox, MVA-BN for RSV (respiratory infection), and TAEK-VAC for certain cancers. The company’s COVID-19/SARS vaccine boosters have shown effectiveness 6 months after dosing. Written by Jeffrey Neal JohnsonRead More BVNRY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BVNRY Stock News HeadlinesMay 27 at 6:55 PM | msn.comBavarian Podcast Works S6E46: Vincent Kompany and Hansi Flick could be joining Bayern Munich and FC Barcelona at dangerous periods in each club’s history; Which Bayern ...May 27 at 6:55 PM | msn.comBavarian Loan Works: Two domestic doublesMay 22, 2024 | finance.yahoo.comCapital Increase in Bavarian Nordic A/S as a Result of Employee Warrant ExerciseMay 21, 2024 | finanznachrichten.deBavarian Nordic A/S: EVP and Chief Medical Officer Laurence de Moerlooze Will Be Leaving Bavarian NordicMay 21, 2024 | finance.yahoo.comBavarian Nordic – Transactions in Connection with Share Buy-Back Program and Termination of Share Buy-Back ProgramMay 21, 2024 | finance.yahoo.comEVP and Chief Medical Officer Laurence de Moerlooze Will Be Leaving Bavarian NordicMay 21, 2024 | americanbankingnews.comBavarian Nordic A/S (OTCMKTS:BVNRY) Share Price Crosses Above Fifty Day Moving Average of $7.53May 8, 2024 | finanznachrichten.deBavarian Nordic A/S: Bavarian Nordic Announces Interim Results for the First Three Months of 2024May 8, 2024 | finance.yahoo.comBavarian Nordic Announces Interim Results for the First Three Months of 2024May 8, 2024 | finance.yahoo.comBavarian Nordic Launches Share Buy-Back Program to Hedge Incentive Scheme ObligationsMay 5, 2024 | finance.yahoo.comBavarian Nordic A/S (BV3A.SG)May 2, 2024 | msn.comBavarian Podcast Works: Weekend Warm-up Show Season 3, Episode 43 — Ralf Rangnick rejected Bayern Munich...now what?; Jonathan Tah to Bayern?; What to expect from round two ...May 1, 2024 | msn.comBavarian Podcast Works — Preview Show: VfB Stuttgart vs. Bayern Munich (Bundesliga)April 30, 2024 | msn.comBavarian Podcast Works — Preview Show: Bayern Munich vs. Real Madrid (Champions League)April 29, 2024 | finanznachrichten.deBavarian Nordic A/S: Bavarian Nordic Receives 65 mEUR Contract to Supply Smallpox Vaccines for EU Strategic ReserveApril 29, 2024 | msn.comBavarian Podcast Works S6E42: Is Bayern Munich becoming too toxic to coach? How Hoeneß’s row with Tuchel might affect the Real Madrid gameApril 29, 2024 | globenewswire.comBavarian Nordic Receives 65 mEUR Contract to Supply Smallpox Vaccines for EU Strategic ReserveApril 29, 2024 | finance.yahoo.comBavarian Nordic Initiates Rolling Submission of Biologics License Application with FDA for its Chikungunya Vaccine CandidateApril 29, 2024 | finanznachrichten.deBavarian Nordic A/S: Bavarian Nordic Initiates Rolling Submission of Biologics License Application with FDA for its Chikungunya Vaccine CandidateApril 27, 2024 | finance.yahoo.comBavarian Nordic A/S (BVNRY)April 22, 2024 | seekingalpha.comBVNKF Bavarian Nordic A/SApril 16, 2024 | finance.yahoo.comResolutions of the Annual General Meeting 2024 of Bavarian Nordic A/SApril 13, 2024 | msn.comWeekend Warm-up: With Serge Gnabry’s future at Bayern Munich uncertain, Chris Führich and Bayern Munich could be getting close; Bundesliga predictions; Throwing it back to ...April 3, 2024 | msn.comBavarian Nordic launches mpox vaccine in United StatesApril 3, 2024 | msn.comBavarian Nordic expands access to mpox vaccine in USSee More Headlines Receive BVNRY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bavarian Nordic A/S and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today5/30/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolOTCMKTS:BVNRY CUSIPN/A CIKN/A Webwww.bavarian-nordic.com Phone(453) 326-8383Fax45-3326-8380Employees1,381Year Founded1994Profitability EPS (Most Recent Fiscal Year)$0.63 Trailing P/E Ratio13.39 Forward P/E Ratio16.22 P/E GrowthN/ANet Income$214.09 million Net Margins14.74% Pretax Margin12.92% Return on Equity16.11% Return on Assets10.79% Debt Debt-to-Equity RatioN/A Current Ratio1.55 Quick Ratio0.94 Sales & Book Value Annual Sales$1.02 billion Price / Sales1.93 Cash Flow$0.03 per share Price / Cash Flow246.38 Book Value$4.77 per share Price / Book1.77Miscellaneous Outstanding Shares234,290,000Free FloatN/AMarket Cap$1.98 billion OptionableNot Optionable Beta1.50 Social Links (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. Paul John Chaplin MSc (Age 57)Ph.D., CEO & President Comp: $2.13MMr. Henrik Juuel M.Sc. (Age 59)CFO & Executive VP Comp: $1.18MMr. Russell Thirsk M.Sc. (Age 56)Executive VP & COO Mr. Rolf Sass SørensenVice President of Investor Relations & CommunicationsMs. Anu Helena Kerns M.Sc. (Age 52)Executive VP and Chief People & Sustainability Officer Mr. Jean-Christophe May M.B.A. (Age 57)Pharm.D., Executive VP & Chief Commercial Officer Dr. Laurence De Moerlooze Ph.D. (Age 60)Executive VP & Chief Medical Officer More ExecutivesKey CompetitorsVaxcyteNASDAQ:PCVXRevolution MedicinesNASDAQ:RVMDExelixisNASDAQ:EXELHalozyme TherapeuticsNASDAQ:HALOCRISPR TherapeuticsNASDAQ:CRSPView All Competitors BVNRY Stock Analysis - Frequently Asked Questions How have BVNRY shares performed in 2024? Bavarian Nordic A/S's stock was trading at $8.7450 on January 1st, 2024. Since then, BVNRY shares have decreased by 3.5% and is now trading at $8.4350. View the best growth stocks for 2024 here. Are investors shorting Bavarian Nordic A/S? Bavarian Nordic A/S saw a drop in short interest in the month of April. As of April 30th, there was short interest totaling 100 shares, a drop of 87.5% from the April 15th total of 800 shares. Based on an average trading volume of 3,100 shares, the short-interest ratio is currently 0.0 days. View Bavarian Nordic A/S's Short Interest. How were Bavarian Nordic A/S's earnings last quarter? Bavarian Nordic A/S (OTCMKTS:BVNRY) issued its earnings results on Wednesday, May, 8th. The company reported ($0.07) EPS for the quarter. The business earned $121.08 million during the quarter. Bavarian Nordic A/S had a trailing twelve-month return on equity of 16.11% and a net margin of 14.74%. How do I buy shares of Bavarian Nordic A/S? Shares of BVNRY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:BVNRY) was last updated on 5/30/2024 by MarketBeat.com Staff From Our PartnersExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceWrite this ticker symbol down…StocksToTradeThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarBiden Nomination CANCELED?The Freeport SocietyBUY ALERT: Tiny tech play partners with US governmentStansberry ResearchGold Set to EXPLODE!Gold Safe Exchange[Urgent!] Generational Wealth GameplanCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bavarian Nordic A/S Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.